L
Lawrence D. True
Researcher at University of Washington
Publications - 321
Citations - 34128
Lawrence D. True is an academic researcher from University of Washington. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 72, co-authored 289 publications receiving 29134 citations. Previous affiliations of Lawrence D. True include United States Department of Veterans Affairs & Emory University.
Papers
More filters
Journal ArticleDOI
Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations
Daniella Bianchi-Frias,Ryan Basom,Jeffrey J. Delrow,Ilsa Coleman,Olga Dakhova,Xiaoyu Qu,Min Fang,Omar E. Franco,Nolan G. Ericson,Jason H. Bielas,Simon W. Hayward,Lawrence D. True,Colm Morrissey,Lisha G. Brown,Neil A. Bhowmick,David R. Rowley,Michael Ittmann,Peter S. Nelson +17 more
TL;DR: The gene expression changes observed in prostate cancer–adjacent stroma and the attendant contribution of the stroma to the development and progression of prostate cancer are not due to frequent or recurrent genomic alterations in the TME.
Journal ArticleDOI
20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy : Preliminary biochemical outcomes from a prospective randomized multi-center trial
Kent E. Wallner,Kent E. Wallner,Kent E. Wallner,Gregory Merrick,Lawrence D. True,Tracey Sherertz,Steven Sutlief,Steven Sutlief,William Cavanagh,Wayne M. Butler +9 more
TL;DR: The randomized data presented here suggests that the likelihood of biochemical cure is similar with standard (44 Gy) or lower dose (20 Gy) supplemental beam radiation, in the setting of a high degree of prostate coverage by the brachytherapy prescription dose.
Journal ArticleDOI
Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.
Kenneth A. Iczkowski,Lars Egevad,Jun Ma,Nicholas Harding-Jackson,Ferran Algaba,Athanase Billis,Philippe Camparo,Liang Cheng,David Clouston,Eva Comperat,Milton W. Datta,Andrew G. Evans,David J. Griffiths,Charles C. Guo,Seife Hailemariam,Wei Huang,Peter A. Humphrey,Zhong Jiang,Hillel Kahane,Glen Kristiansen,Francisco G. La Rosa,Antonio Lopez-Beltran,Gregory T. MacLennan,Cristina Magi-Galluzzi,Jennifer Merrimen,Rodolfo Montironi,Adeboye O. Osunkoya,Maria M. Picken,Nagarjun Rao,Rajal B. Shah,Jonathan H Shanks,Steven S. Shen,Ossama Tawfik,Lawrence D. True,Theodorus van der Kwast,Murali Varma,Thomas M. Wheeler,Debra L. Zynger,Natasha Sahr,David G. Bostwick +39 more
TL;DR: The diagnosis of intraductal carcinoma (IDC) of the prostate remains subjective because 3 sets of diagnostic criteria are in use: lumen-spanning proliferation of neoplastic cells in preexisting ducts with a dense cribriform or partial solid growth pattern.
Journal ArticleDOI
Tissue-of-origin-specific gene repositioning in breast and prostate cancer
Karen J. Meaburn,Olufunmilayo Agunloye,Michelle Devine,Marc Leshner,Gregory W. Roloff,Lawrence D. True,Tom Misteli +6 more
TL;DR: It is found that tissue-specific organization of the genome in normal breast and prostate with 40 % of genes occupying differential positions between the two tissue types indicates that gene repositioning in cancer is tissue-of-origin specific.
Journal ArticleDOI
Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.
Colm Morrissey,Alex Dowell,Theodore D. Koreckij,Holly M. Nguyen,Bryce Lakely,William C. Fanslow,Lawrence D. True,Eva Corey,Robert L. Vessella,Robert L. Vessella +9 more
TL;DR: It is hypothesized that the inhibition of angiopoietin‐2 activity in PCa will impede angiogenesis, tumor growth, and alter bone response in vivo.